Monovich A, Gurumurthy A, Ryan R
Adv Exp Med Biol. 2024; 1459:291-320.
PMID: 39017849
DOI: 10.1007/978-3-031-62731-6_13.
Zapilko V, Moisio S, Parikka M, Heinaniemi M, Lohi O
Cancers (Basel). 2023; 15(24).
PMID: 38136366
PMC: 10871125.
DOI: 10.3390/cancers15245821.
Ray S, Hewitt K
Bioessays. 2023; 45(8):e2300022.
PMID: 37318311
PMC: 10527593.
DOI: 10.1002/bies.202300022.
Kaczmarska A, Derebas J, Pinkosz M, Niedzwiecki M, Lejman M
Cells. 2023; 12(3).
PMID: 36766699
PMC: 9913634.
DOI: 10.3390/cells12030357.
Lu D, Ellegast J, Ross K, Malone C, Lin S, Mabe N
Nat Cell Biol. 2023; 25(2):285-297.
PMID: 36658220
PMC: 9928584.
DOI: 10.1038/s41556-022-01059-8.
ETV6 Deficiency Unlocks ERG-Dependent Microsatellite Enhancers to Drive Aberrant Gene Activation in B-Lymphoblastic Leukemia.
Kodgule R, Goldman J, Monovich A, Saari T, Aguilar A, Hall C
Blood Cancer Discov. 2022; 4(1):34-53.
PMID: 36350827
PMC: 9820540.
DOI: 10.1158/2643-3230.BCD-21-0224.
Elevated ETV6 Expression in Glioma Promotes an Aggressive In Vitro Phenotype Associated with Shorter Patient Survival.
Xiong Z, Wu S, Li F, Luo C, Jin Q, Connolly I
Genes (Basel). 2022; 13(10).
PMID: 36292767
PMC: 9656946.
DOI: 10.3390/genes13101882.
Childhood B-Cell Preleukemia Mouse Modeling.
Isidro-Hernandez M, Aleman-Arteaga S, Casado-Garcia A, Ruiz-Corzo B, Riesco S, Prieto-Matos P
Int J Mol Sci. 2022; 23(14).
PMID: 35886910
PMC: 9317949.
DOI: 10.3390/ijms23147562.
Current insights into the role of Fli-1 in hematopoiesis and malignant transformation.
Ben-David Y, Gajendran B, Sample K, Zacksenhaus E
Cell Mol Life Sci. 2022; 79(3):163.
PMID: 35412146
PMC: 11072361.
DOI: 10.1007/s00018-022-04160-1.
Identification of new ETV6 modulators through a high-throughput functional screening.
Neveu B, Richer C, Cassart P, Caron M, Jimenez-Cortes C, St-Onge P
iScience. 2022; 25(3):103858.
PMID: 35198911
PMC: 8851229.
DOI: 10.1016/j.isci.2022.103858.
Genetics and Diagnostic Approach to Lymphoblastic Leukemia/Lymphoma.
Afkhami M, Ally F, Pullarkat V, Pillai R
Cancer Treat Res. 2021; 181:17-43.
PMID: 34626353
DOI: 10.1007/978-3-030-78311-2_2.
Autophagy and Metabolism in Normal and Malignant Hematopoiesis.
Stergiou I, Kapsogeorgou E
Int J Mol Sci. 2021; 22(16).
PMID: 34445246
PMC: 8395194.
DOI: 10.3390/ijms22168540.
A dual role for DNA binding by Runt in activation and repression of transcription.
Prazak L, Iwasaki Y, Kim A, Kozlov K, King K, Gergen J
Mol Biol Cell. 2021; 32(21):ar26.
PMID: 34432496
PMC: 8693977.
DOI: 10.1091/mbc.E20-08-0509.
Novel insights into the impact of the SUMOylation pathway in hematological malignancies (Review).
Wang L, Qian J, Yang Y, Gu C
Int J Oncol. 2021; 59(3).
PMID: 34368858
PMC: 8360622.
DOI: 10.3892/ijo.2021.5253.
An updated account on molecular heterogeneity of acute leukemia.
Rahul E, Goel H, Chopra A, Ranjan A, Gupta A, Meena J
Am J Blood Res. 2021; 11(1):22-43.
PMID: 33796387
PMC: 8010602.
Diagnostic Utility of IGF2BP1 and Its Targets as Potential Biomarkers in ETV6-RUNX1 Positive B-Cell Acute Lymphoblastic Leukemia.
Sharma G, Boby E, Nidhi T, Jain A, Singh J, Singh A
Front Oncol. 2021; 11:588101.
PMID: 33708624
PMC: 7940665.
DOI: 10.3389/fonc.2021.588101.
Different mutant RUNX1 oncoproteins program alternate haematopoietic differentiation trajectories.
Kellaway S, Keane P, Edginton-White B, Regha K, Kennett E, Bonifer C
Life Sci Alliance. 2021; 4(2).
PMID: 33397648
PMC: 7812315.
DOI: 10.26508/lsa.202000864.
Identification of novel fusion transcripts in meningioma.
Khan A, Gadot R, Shetty A, Bayley 5th J, Hadley C, Cardenas M
J Neurooncol. 2020; 149(2):219-230.
PMID: 32949309
PMC: 7553203.
DOI: 10.1007/s11060-020-03599-1.
Revisiting NTRKs as an emerging oncogene in hematological malignancies.
Joshi S, Davare M, Druker B, Tognon C
Leukemia. 2019; 33(11):2563-2574.
PMID: 31551508
PMC: 7410820.
DOI: 10.1038/s41375-019-0576-8.
RUNX family: Oncogenes or tumor suppressors (Review).
Otalora-Otalora B, Henriquez B, Lopez-Kleine L, Rojas A
Oncol Rep. 2019; 42(1):3-19.
PMID: 31059069
PMC: 6549079.
DOI: 10.3892/or.2019.7149.